PubMed
Semax and its derivatives: neuroprotective peptides (review)
Ashmarin et al., 2018
Neurological & CognitiveResearch OnlyS
Adamax
Semax-family Analog
Nootropic research peptide in the Semax-family class; limited direct clinical evidence.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- S
- Community score
- 227
- Trackers
- 4,670
Trend index
Overview
About Adamax
Nootropic research peptide in the Semax-family class; limited direct clinical evidence.
- Category
- Neurological & Cognitive
- Regulatory status
- Research Only
- Also known as
- Semax-family Analog
- Self-reports
- 24
Community
What 24 users report
24 community reports
Positive 98% · Neutral 2% · Negative 0%
Most reported benefits
Energy
171
Cognition
171
Most reported side effects
Headache
4
Dose distribution
Median: 600–1000 mcg · Most common: 200–400 mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
59
400–600
12
600–1000
50
1000–2000
50
2000+
0
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
Research
Cited research (2)
Source
PubMed
Semax, an analog of ACTH(4-7), regulates expression of immune response genes
Dmitrieva et al., 2013
Help
Frequently asked
What do PeptIQ users report about Adamax?
This page summarizes 24 anonymized self-reports from PeptIQ users who track Adamax, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for Adamax?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Adamax safe to use?
This wiki does not assess safety or recommend use. Adamax is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Adamax?
Research, primarily in animal models, suggests Adamax may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Adamax?
Adamax is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Adamax as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Adamax?
The safety and effectiveness of Adamax have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Adamax?
While there are over 200 published studies on Adamax, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source